These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 9530547

  • 1. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Gunasekara NS, Faulds D.
    Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
    [Abstract] [Full Text] [Related]

  • 2. Mature results from three large controlled studies with raltitrexed ('Tomudex').
    Cunningham D.
    Br J Cancer; 1998 Mar; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
    Sato A, Kurihara M, Horikoshi N, Aiba K, Kikkawa N, Shirouzu K, Mitachi Y, Sakata Y, Wakui A.
    Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
    [Abstract] [Full Text] [Related]

  • 4. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM.
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [Abstract] [Full Text] [Related]

  • 5. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ.
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [Abstract] [Full Text] [Related]

  • 6. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
    Zalcberg J.
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S17-22. PubMed ID: 9376633
    [Abstract] [Full Text] [Related]

  • 7. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
    Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Budillon A.
    Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
    [Abstract] [Full Text] [Related]

  • 8. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N, Aiba K, Fukuoka M, Akazawa S, Sakata Y, Furuse K, Kanamaru R, Kudoh S, Konishi T, Kurihara M, Niitani H, Furue H, Tsukagoshi S, Taguchi T, Yoshida S, Ota K, Kotake T, Wakui A.
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Drug resistance in colon cancer.
    Gorlick R, Bertino JR.
    Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
    [Abstract] [Full Text] [Related]

  • 14. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.
    Cunningham D, Zalcberg J, Maroun J, James R, Clarke S, Maughan TS, Vincent M, Schulz J, González Barón M, Facchini T.
    Eur J Cancer; 2002 Mar; 38(4):478-86. PubMed ID: 11872339
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies.
    Judson IR.
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S5-9. PubMed ID: 9376637
    [Abstract] [Full Text] [Related]

  • 17. Raltitrexed: optimism and reality.
    Wilson KS, Malfair Taylor SC.
    Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1447-54. PubMed ID: 19863453
    [Abstract] [Full Text] [Related]

  • 18. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
    Ford HE, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, Calvert AH, Judson IR, Jackman AL.
    Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
    [Abstract] [Full Text] [Related]

  • 19. Raltitrexed-based chemotherapy for advanced colorectal cancer.
    Liu Y, Wu W, Hong W, Sun X, Wu J, Huang Q.
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):219-25. PubMed ID: 24388340
    [Abstract] [Full Text] [Related]

  • 20. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
    Tsavaris N, Kosmas C, Vadiaka M, Koufos C.
    BMC Cancer; 2002 Apr; 2():2. PubMed ID: 11860608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.